Health industry leaders still adjusting to the policy rules of President Trump's Washington face another potential shift in November's midterm elections, which are likely to reshape federal health policy debates from Medicaid funding to prescription drug pricing.

The stakes are especially high if Democrats seize control of a chamber of Congress, though any major legislation would still require Trump's signature to become law. That constraint limits how far a flipped chamber could push policy, but it does not eliminate the leverage that new committee leadership would gain over hearings, oversight, and agenda-setting.

The assessment draws on interviews with nearly a dozen leaders and lobbyists representing the health industry, who identified the most consequential questions about federal policy after the midterms. Three issues stand out for their reach across the U.S. health system, the research enterprise, and patient access: drug pricing, Medicaid funding, and federal research funding.

For pharmaceutical companies and biotech firms, the post-election posture of Congress on drug pricing will shape portfolio and pricing strategy. Lawmakers in both parties have shown willingness to pressure manufacturers over the cost of medication, and a changed Congress could accelerate or redirect that pressure. How the question resolves will affect revenue models for developers and, ultimately, what patients pay at the pharmacy counter.

Medicaid funding represents a second flashpoint. Any moves to restructure or cut the program would ripple through hospital finances, insurer operations, and state budgets. Industry lobbyists flagged Medicaid as one of the key policy questions whose resolution after November will have wide-ranging impacts.

Federal research funding rounds out the list. For academic institutes, university laboratories, and their vendor and publishing partners, the level and direction of federal science spending after the midterms will influence grant pipelines, hiring plans, and long-term portfolio commitments. R&D managers planning multi-year budgets will need to watch how appropriations dynamics shift if control of a chamber changes hands.

The industry leaders interviewed framed these questions as unresolved rather than predetermined. Election outcomes will determine who controls the committees that write health and science legislation, but the requirement for presidential approval means the most likely near-term changes involve oversight, hearings, and negotiated compromises rather than sweeping statutory overhauls.

What is clear from the reporting is the breadth of exposure. How these federal policy questions are answered in the months after November will affect America's health system, the scientific enterprise, and patients — a scope that extends well beyond Washington's health lobby to laboratory benches, hospital finance offices, and biotech boardrooms.

The full analysis, based on STAT's interviews with the industry leaders and lobbyists, details how each of these policy questions is likely to develop depending on the election results.